1129 GMT - Sanofi's mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 07:29 ET (11:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。